[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=71f7ccc28a10ee9dcccbb77fb7a5fe5d61d05f0afc0090c8c94ff4c0eccd7701",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753288800,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 136072682,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=71f7ccc28a10ee9dcccbb77fb7a5fe5d61d05f0afc0090c8c94ff4c0eccd7701"
    }
  },
  {
    "ts": null,
    "headline": "Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?",
    "summary": "Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.",
    "url": "https://finnhub.io/api/news?id=05d231aa9423b7481458c60ee5d7fffd3456c3d5c2891baadb669993f07f7b4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753282440,
      "headline": "Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?",
      "id": 136062147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.",
      "url": "https://finnhub.io/api/news?id=05d231aa9423b7481458c60ee5d7fffd3456c3d5c2891baadb669993f07f7b4b"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Bristol-Myers: “Never Seen it This Cheap”",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the lightning round, Cramer replied that he is holding out hope for the company’s “central nervous system drug.” “Bristol Myers, never seen it this cheap. We’re holding it. I did have high hopes for their, what, […]",
    "url": "https://finnhub.io/api/news?id=63863ff6eb956fcd320bbea6b1535530c33279744f595ef99fbc00f4649886b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753282321,
      "headline": "Jim Cramer on Bristol-Myers: “Never Seen it This Cheap”",
      "id": 136062596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the lightning round, Cramer replied that he is holding out hope for the company’s “central nervous system drug.” “Bristol Myers, never seen it this cheap. We’re holding it. I did have high hopes for their, what, […]",
      "url": "https://finnhub.io/api/news?id=63863ff6eb956fcd320bbea6b1535530c33279744f595ef99fbc00f4649886b9"
    }
  },
  {
    "ts": null,
    "headline": "Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?",
    "summary": "Merck's Keytruda drives nearly half of its pharma sales. Investors eye Q2 momentum amid existing competition.",
    "url": "https://finnhub.io/api/news?id=b014c41bc7930cd958e99b1a89cdbde7dc31a5a891f44d9b6910fcf65d820749",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753280700,
      "headline": "Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?",
      "id": 136062252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Merck's Keytruda drives nearly half of its pharma sales. Investors eye Q2 momentum amid existing competition.",
      "url": "https://finnhub.io/api/news?id=b014c41bc7930cd958e99b1a89cdbde7dc31a5a891f44d9b6910fcf65d820749"
    }
  },
  {
    "ts": null,
    "headline": "Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings",
    "summary": "PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.",
    "url": "https://finnhub.io/api/news?id=68a47e716813bab84ba2240659b98a6d1253986406d1de3d41df947c154337f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753280040,
      "headline": "Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings",
      "id": 136062449,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.",
      "url": "https://finnhub.io/api/news?id=68a47e716813bab84ba2240659b98a6d1253986406d1de3d41df947c154337f7"
    }
  }
]